|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To identify AR as a potential therapeutic target, the ASC-J9 was used to re-sensitize paclitaxel-resistant EOC tumors upon paclitaxel treatment in vitro and in vivo.
|
30986993 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that serum deprivation during the culture of 40K-ASCs or during the washing step of 5K-ASCs can induce IFN-β and/or TRAIL expression, ultimately leading to the tumor suppression capability of ASCs.
|
30393160 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia.
|
29132873 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mRNA expression levels of the amino acid transporters of system A (SLC38A1 and SLC38A2), system L (SLC7A5) and system ASC (SLC1A5) were higher in all eight tumors than in the normal lung, with widely varying expression patterns.
|
30334568 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ASC/TMS1 tumor specific methylation may be a useful biomarker for designing improved diagnostic and therapeutic strategies for RCC.
|
26093088 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ASC amino-acid transporter 2 (ASCT2) is a major glutamine transporter that has an essential role in tumour growth and progression.
|
24603303 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using various human PCa cell lines and three different mouse models, we concluded that targeting PCa non-stem/progenitor cells with AR degradation enhancer ASC-J9 and targeting PCa stem/progenitor cells with 5-azathioprine and γ-tocotrienol resulted in a significant suppression of the tumors at the castration resistant stage.
|
22831834 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Atypical squamous cells of undetermined significance (ASC-US) is a broad diagnostic category that could be attributed to human papillomavirus infection (HPV), malignant neoplasia and reactive conditions.
|
22808295 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Quantitative methylation analysis in prostate tissues identified 5 genes (BNIP3, CDKN2A, DCR1, DCR2 and TMS1) which were frequently methylated in tumors but were unmethylated in 100% of benign tissues.
|
20564325 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results.
|
20833385 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TMS1 is a tumor suppressor gene that encodes for caspase recruitment domain containing regulatory protein and has been shown to be hypermethylated in various cancers.
|
20926535 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A total of 65 CpG sites were examined in six tumor suppressor genes: PYCARD (also known as ASC or TMS1), CDH1, GSTP1, RBP1 (also known as CRBP1), SFRP1, and RASSF1.
|
20716965 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The tumor suppressor gene TMS1 (target of methylation-induced silencing) has been described in the literature as a pro-apoptotic gene.
|
19661336 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A three-member fingerprint of S100P-correlated genes, consisting of GPRC5A, FXYD3, and PYCARD, conferred poor outcome in multiple breast cancer data sets, irrespective of estrogen receptor status but dependent on tumor size (P < 0.01).
|
19789341 |
2009 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Aberrant methylation of TMS1 and DAPK genes was detected in 26 (32.1%) tumors and in 18 (22.2%) tumors, respectively.
|
17943730 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
|
17471463 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thirteen genes were analyzed for DNA methylation: the pro-apoptotic CASP8, CASP3, CASP9, DcR1, DR4, DR5 and TMS1; the cell adherence CDH1 and CDH13; the candidate tumor suppressor RASSF1A and BLU; the cell cycle regulator CHFR and the DNA repair MGMT.
|
17272309 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ASC/TMS1 is a pro-apoptotic gene that has been shown to be methylated in many different human neoplasms.
|
17986858 |
2007 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The overall TMS1/ASC methylation rate in the 57 analyzed tumors was 21.05%.
|
17048097 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TMS1 (Target of Methylation induced Silencing), also known as ASC (Apoptosis Speck like protein containing a CARD) is a tumor suppressor gene which encodes for a CARD (caspase recruitment domain) containing regulatory protein and has been shown to promote apoptosis directly and by activation of downstream caspases.
|
16848908 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further analysis of primary tumors indicated that the frequency of hypermethylation was high for ASC (82%) and PAX3 (86%) in all tumor types, and high for RIPK3 in small cell carcinoma (57%).
|
16435073 |
2006 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
ASC methylation in normal tissue was always accompanied with ASC methylation in matching tumor tissue.
|
16870048 |
2006 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Of 58 prostate cancer specimens, methylation of the ASC promoter region was present in 65% of primary cancer tissue, 64% (7/11) of cancer-associated high grade-prostatic intraepithelial neoplasia (HG-PIN), and 28% of normal-appearing but adjacent to tumor prostate tissue.
|
16425203 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the promoters of the selected tumor suppressor genes p73 (48%), p16 (33%), CHFR (19%), p15 (10%), and TMS1 (10%) were hypermethylated in CTCL.
|
15897551 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylation of TMS1 may prove to be a useful prognostic marker and/or predictor of patient survival and tumor malignancy.
|
15466382 |
2004 |